AB04030
12 april 2021
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of Masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg…
Archief
AB11002
A prospective, multicenter, randomised, open-label, active controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor…
ALEPRO
5 februari 2025
AMCOR
4 juni 2025
SSTR2 imaging with [68Ga]Ga-DOTA-TOC PET/CT in NPC Towards improved therapy selection and targeted treatment for NAsopharyngeal CArcinoma. A proof-of-concept pilot study for SOmatostatin Receptor 2 imaging with [68Ga]Ga-DOTA-TOC…
Amgen509 20230005_Xalute
6 juni 2025
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-Resistant Prostate Cancer Samenvatting Xaluritamig is een op STEAP1 (six transmembrane…
Anthos studies met factor IX remmers
1 mei 2023
Apa Enza Short studie
8 april 2024
Studiecoördinator Bij vragen of verwijzingen graag contact opnemen met de studiecoördinator. Dr. M. van Kruchten Afdeling Medische Oncologie Tel: 050 3612821 (secretariaat Oncologie) E-mail: m.van.kruchten@umcg.nl
Apollo
25 april 2024
Archipelago – OncoLifeS
18 maart 2022
Studiecoördinator Bij vragen of verwijzingen graag contact opnemen met de studiecoördinator. Prof. Dr. A.K.L. Reyners Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: a.k.l.reyners@umcg.nl
ARTFORCE
12 april 2021
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE. A randomized study with concomitant cisplatin and standard or adaptive high dose radiotherapy for advanced head and neck…
BAY22143 Actinium
19 juni 2024
Studiecoördinator Bij vragen of verwijzingen graag contact opnemen met de studiecoördinator. Dr. D.G. Knapen Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: d.g.knapen@umcg.nl Dr. D.J.A. de Groot Afdeling…
BI-1403-0002
24 januari 2023
A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors Protocol:…
BI-1403-0002
A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors Protocol:…
BLU-667
12 april 2021
CA209-8UU Imaging
PD-L1 PET imaging in patients with an inoperable melanoma or NSCLC with brain metastasis and eligible for treatment with nivolumab. CA209-8UU imaging Protocolnummer: 2016255-322 EudraCT nummer: 2016-002308-22 METc…
CA209-8UU Imaging
CAIRO 4
The role of surgery of the primary tumour with few or -absent symptoms in patients with synchronous unresectable metastases of colon cancer, a randomized phase III study. METcnummer:…
CAIRO5
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases. CAIRO5, a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG) Eudract nummer: 2013-005435-24 METc…
CD8 PET Imaging in metastatic solid tumours
13 december 2024
A phase II, open label, multi-center study of 89Zr-Df-crefmirlimab for CD8 positron emission 11 tomography in patients with locally advanced or metastatic solid tumours Samenvatting Multicenterstudie Single-arm Fase…
CD8 PET imaging studie (GENENTECH)
12 april 2021
Een fase 1-2 immunoPET imaging studie met ZED88082A/CED88004S in patiënten voor en tijdens behandeling met 1) MPDL3280A of 2) PD-1 antilichaam met of zonder ipilimumab. Protocolnummer: Eudract nummer:…